Moderna (NASDAQ:MRNA) Price Target Cut to $99.00 by Analysts at The Goldman Sachs Group

Moderna (NASDAQ:MRNA) had its price target cut by The Goldman Sachs Group from $112.00 to $99.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts also recently weighed in on MRNA. Wolfe Research initiated coverage on shares of Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target on the stock. Argus downgraded shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Bank of America reissued an “underperform” rating and set a $41.00 price target on shares of Moderna in a report on Tuesday, December 10th. Barclays dropped their price objective on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Finally, HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research note on Monday, November 18th. Four analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $69.79.

Moderna Trading Up 7.9 %

Shares of MRNA stock opened at $44.94 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company has a market cap of $17.29 billion, a price-to-earnings ratio of -7.72 and a beta of 1.60. Moderna has a 1 year low of $31.94 and a 1 year high of $170.47. The firm has a fifty day moving average price of $40.79 and a 200-day moving average price of $62.18.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the prior year, the business posted ($1.39) earnings per share. The business’s quarterly revenue was up 3.8% on a year-over-year basis. As a group, equities analysts predict that Moderna will post -9.27 earnings per share for the current year.

Insider Activity

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders have sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Moderna

Large investors have recently made changes to their positions in the company. Blue Trust Inc. lifted its stake in Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after purchasing an additional 574 shares during the last quarter. Wilmington Savings Fund Society FSB lifted its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares during the last quarter. Larson Financial Group LLC boosted its holdings in Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after acquiring an additional 317 shares during the period. Rakuten Securities Inc. grew its position in Moderna by 477.3% in the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after acquiring an additional 778 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its stake in Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.